Erlonat contains Erlotinib, an oral anticancer medicine used to treat certain types of lung and pancreatic cancers. It belongs to the class of tyrosine kinase inhibitors (TKIs). Erlonat specifically targets cancer cells that have abnormalities in the epidermal growth factor receptor (EGFR) pathway, which promotes tumor growth and survival.

Mechanism of action:
Erlotinib blocks the EGFR tyrosine kinase enzyme in cancer cells. This enzyme normally sends signals that stimulate cell growth, division, and survival. By inhibiting EGFR, Erlonat slows or stops the growth of cancer cells and may also induce cancer cell death.

Uses:

• Non-small cell lung cancer (NSCLC) with specific EGFR mutations, often in advanced or metastatic stages

• Pancreatic cancer in combination with gemcitabine for locally advanced, unresectable, or metastatic disease

Adverse effects:
Common side effects include skin rash, acne-like eruptions, dry skin, itching, diarrhea, nausea, vomiting, loss of appetite, and fatigue. Less common but serious side effects can include lung inflammation (interstitial lung disease), severe liver problems, eye irritation, or bleeding. Patients may also experience infections or electrolyte imbalances.